2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Biological Processes, Apoptosis, Metabolism, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult, Elderly
PAPER

5160 APL-4098, a first-in-class GCN2 inhibitor, in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome/AML (MDS/AML): Preliminary results from an ongoing phase 1 study

Richard Dillon, MBBS, David C. Taussig, PhD,MRCP,FRCPath2, Shuh Ying Tan, MBBS, FRACP, FRCPA3, Chong Chyn Chua, MBBS BMedSc PhD FRACP FRCPA4, Hun Chuah5, Steven Knapper, DM, FRCPath, MBBChir6, Mhairi Copland, PhD, FRCP, FRCPath, MBBChir, MBChB7, Rueben Amofa8, Laurie Green9, Misba Beerahee10, Brian Hamilton, MD11, Nadine Clemo, PhD12, Sanjay Aggarwal, MD13, Shaun Fleming, MBBS (Hons), PhD14
1 Guy's Hospital, London, United Kingdom, Kings College, London, United Kingdom
2 Royal Marsden, London, United Kingdom
3 St. Vincent's Hospital, Melbourne, Australia
4 Monash Hospital, Clayton, Australia
5 Royal Perth Hospital, Perth, Australia
6 Cardiff University, Penarth, United Kingdom
7 Gartnavel General Hospital, Glasglow, United Kingdom
8 Sarah Cannon Research Institute, London, United Kingdom
9 Apollo Therapeutics Ltd, Boston, United States
10 MBPharmaco Consulting Ltd, London, United Kingdom
11 BioPharm Solutions inc, Newton, Massachusetts, United States
12 Apollo Therapeutics Ltd, Cambridge, United Kingdom
13 Apollo Therapeutics Ltd, Boston, United States
14 Alfred Hospital, Melbourne, Australia, Monash University, Melbourne, Australia

Background: The GCN2 (General Control Nonderepressible 2) arm of the integrated stress response (ISR) is activated to allow leukemic cells to adapt and survive under conditions of amino acid deficiency. APL-4098 is a potent, selective first-in-class small molecule inhibitor of GCN2 that suppresses ISR signaling, leading to depletion of leukemic stem cells, which are highly dependent on amino acid metabolism. In an AML patient-derived xenograft model, APL-4098 demonstrated synergistic efficacy when combined with venetoclax (ven). In the monotherapy portion of the phase 1 study, APL-4098 was shown to be safe and well-tolerated up to 100 mg administered orally once daily, with demonstration of pharmacodynamic (PD) activity. Twenty-eight patients with relapsed / refractory (R/R) AML and high-risk MDS were treated with APL-4098 at doses ranging from 20 – 150 mg with dose limiting toxicities (DLT) observed at the 150 mg dose level. Preliminary activity, acceptable safety and determination of a potential recommended phase 2 dose (RP2D) led to the opening of combination cohorts. Here, we report preliminary safety, pharmacokinetic (PK) and efficacy results from the ongoing phase 1 study of APL-4098 in combination with ven and azacitidine (aza) in AML patients.

Methods: This is an ongoing, open-label, phase 1 study evaluating APL-4098 in combination with ven + aza in adult patients with R/R AML who have no available therapies known to provide clinical benefit, and in newly diagnosed (ND) AML patients who are ineligible for intensive chemotherapy. The primary objectives are to evaluate safety and tolerability using the Bayesian Optimal Interval (BOIN) design, with the aim to determine the RP2D. Additional objectives include assessment of preliminary efficacy and PK of APL-4098 (NCT06372717). The results of the first 8 R/R AML patients will be presented.

Results: As of 23 July 2026, 8 R/R AML patients have been treated with 40mg APL-4098 in combination with 400 mg venetoclax and 75 mg/m2 azacitidine. Median age was 68 years (range: 34-78), and 5 patients (63%) were female. Six patients (75%) were White, 1 (13%) Asian, and 1 (13%) Black or African American; all were non-Hispanic/non-Latino. Four (50%) patients had secondary AML and 5 (62%) had adverse genetics as per ELN 2022 risk classification.  The median prior lines of therapy were 1 (range: 1-3); 4 (50%) had prior ven + aza, and 3 (38%) were refractory to their last line. The median duration of treatment was 58 days (range: 15-137), with 2 patients still active on APL-4098 + ven + aza. One DLT of Grade 3 fatigue occurred in a single patient leading to discontinuation of treatment (DLT rate: 13%). Treatment-emergent adverse events (TEAEs) have been predominantly grades 1 and 2. Most frequently observed TEAEs suspected to be related to APL-4098 in the triplet combination are diarrhoea and nausea, with no Grade 3 events observed and one SAE of diarrhoea. All 8 patients were evaluable for disease assessment. One patient achieved a Complete Remission (CR), two patients achieved a Complete Remission with incomplete count recovery (CRi), one patient achieved a Partial Response (PR), and one patient was deemed to be morphologically leukemia-free (MFLS). Two patients went on to receive an allogeneic stem cell transplant (alloSCT). Steady-state APL-4098 systemic exposure following the triplet therapy was comparable to that observed with APL-4098 monotherapy supporting the absence of a clinically meaningful drug-drug PK interaction.

Conclusion: APL-4098, an oral potent inhibitor of GCN2, has been demonstrated to have a favourable tolerability and safety profile across 20 - 100 mg dose range as monotherapy in R/R AML patients. Here we show that 40 mg APL-4098 is tolerated in combination with ven + aza. PK analyses demonstrated plasma exposures consistent with sustained pharmacologically active concentrations following once-daily dosing. In the R/R patient population encouraging clinical responses have been reported in 5 out of 8 evaluable patients with 2 patients proceeding to alloSCT. These findings support continued clinical development of APL-4098 in combination with ven + aza; enrolment into both R/R and newly diagnosed AML cohorts is ongoing.

Nadine Clemo, PhD: No relevant conflicts of interest to declare.